The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Safety was equally impressive. ENV-294 was well tolerated
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
Revolutionary technology will further boost OneSource’s scientific services offerings
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
Subscribe To Our Newsletter & Stay Updated
